CONGRESS GUIDE

ERS International Congress 2016
OUTLINE PROGRAMME
TUESDAY 06 SEPTEMBER, 2016
T-05 12:50 14:40 582 TP Latest insights into the management of chronic respiratory diseases
T-06 12:50 14:40 583 TP Latest insights into chronic care
T-07 12:50 14:40 584 TP Hospitalisation and comorbidities in chronic lung diseases
T-08 12:50 14:40 585 TP A view into a chest and pleural pathology
T-09 12:50 14:40 586 TP Mixed-up imaging of various chest diseases
T-10 12:50 14:40 587 TP Airway stenting and ablation
T-11 12:50 14:40 588 TP EBUS and transthoracic ultrasound
T-12 12:50 14:40 589 TP Orphan diseases I
T-13 12:50 14:40 590 TP ILD: from the bench to the bedside
T-14 12:50 14:40 591 TP Orphan diseases II
T-15 12:50 14:40 592 TP Screening, diagnosis, assessment, and treatment of COPD in primary care
T-16 12:50 14:40 593 TP Targeting care, pulmonary rehabilitation, management, and self-management of COPD
exacerbations in primary care
T-17 12:50 14:40 594 TP Airway response to infection
T-18 12:50 14:40 595 TP Studies in airway cell biology
T-19 12:50 14:40 596 TP New signalling pathways in COPD
T-20 12:50 14:40 597 TP Common mechanisms in lung development and fbrosis
T-21 12:50 14:40 598 TP Novel avenues in the treatment of COPD I
T-22 12:50 14:40 599 TP Novel avenues in the treatment of COPD II
T-23 12:50 14:40 600 TP Preclinical pharmacology: drug targets and mechanisms of action
T-24 12:50 14:40 601 TP Asthma management
T-25 12:50 14:40 602 TP Functional assessment of the airways
T-26 12:50 14:40 603 TP Monitoring comorbidities
T-27 12:50 14:40 604 TP Phenotyping and monitoring airway diseases
T-28 12:50 14:40 605 TP Clinical studies in asthma and immunology
T-29 12:50 14:40 606 TP Asthma: treatment, disease control, and quality of life
T-30 12:50 14:40 607 TP Prevalence of obstructive airway diseases, methods of diagnosis, and lung function testing
T-31 12:50 14:40 608 TP Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to
late-onset Pompe’s disease
T-32 12:50 14:40 609 TP Occupational and environmental exposures and biomarkers: human studies, animal data, and
in vitro methods
T-33 12:50 14:40 610 TP Te indoor and ambient environments
T-34 12:50 14:40 611 TP Smoking cessation strategies
T-35 12:50 14:40 612 TP Smoking-related diseases
T-36 12:50 14:40 613 TP Latest advances in paediatric sleep medicine
T-37 12:50 14:40 614 TP Techniques and tools in paediatric asthma
T-38 12:50 14:40 615 TP Living with asthma around the globe
T-39 12:50 14:40 616 TP Te future of lung function is beginning now
T-40 12:50 14:40 617 TP Physiotherapy interventions and assessment options in hospitalised patients
T-41 12:50 14:40 618 TP Treatment and assessment of functional outcomes in cardiorespiratory physiotherapy
EPIDEMIOLOGY/
ENVIRONMENT
INFECTION
INTENSIVE CARE
ONCOLOGY
PAEDIATRIC
PHYSIOLOGY
SLEEP
INDUSTRY
ROOM TIME SESSION PRICE
Room E
13:00 14:30 619 Lunchtime session
Early life origins of asthma and COPD: ERS/NEJM Lunchtime
session
Prince Regent
Room
13:00 14:30 620 Lunchtime session
Should we start screening programmes in Europe? Review of current
scientifc evidence
Room L
13:00 14:30 621 Lunchtime session
GOLD: novel approaches to COPD assessment and management
Room B
13:00 14:30 622 Lunchtime session
Do we really need PD1/PD-L1 status and next generation sequencing
to treat lung cancer? Pro/con discussions
Room K
13:00 14:30 623 ERS Meeting
Room ICC Capital
Suite 7
ERS General Assembly Meeting
13:00 14:30 624 Educational forum
Recertifcation of respiratory professionals: current practice and the
future
Clinical
Clinical
37